One of the most promising developments in NSCLC treatment is the targeting of KRAS mutations, which occur in 20–25% of cases and have historically been regarded as “undruggable”, particularly the KRAS-G12C mutation [2–4]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.